Effect of Brahmi vati in Schizophrenia
Phase 2
- Conditions
- Health Condition 1: F200- Paranoid schizophrenia
- Registration Number
- CTRI/2024/03/064540
- Lead Sponsor
- Dr Dhanu S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Subjects fulfilling DSM-V Diagnosis of Schizophrenia and Psychotic disorders.
Receiving a stable dose of Antipsychotic agents for =4weeks.
Symptom exacerbation had to extend =2weeks but =1 year .Participants will be enrolled only if their PANSS total score is =60.
Patients who are on anti-psychotics as well as anticholinergic medications.
Exclusion Criteria
Pregnancy or breastfeeding.
Organic psychotic disorders.
Patients who have received Electro-convulsive therapy.
Known case of BPH.
patients whose serum creatinine is greater than 1.5mg/dl.
Already diagnosed co-morbidities like unsatisfactory control of Diabetes mellitus
FBS greater than 125mg/dl or PPBS greater than 180mg/dl or HbA1C greater than 7 Hypertension
greater than 140/90mmHg.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PANSS(Positive And negative syndrome scale)Timepoint: Baseline, 15th,30th,45th and 60th day. <br/ ><br>
- Secondary Outcome Measures
Name Time Method MoCA (Montreal cognitive assessment) <br/ ><br>PSQI (Pitts Burg sleep quality index) <br/ ><br>CDSS (Calgary depression scale for schizophrenia) <br/ ><br>WHOQOL-BREF (Quality of life) <br/ ><br>CGI (Clinical Global Impression Scale) <br/ ><br>UKU side effect scale[24]Timepoint: Baseline, 15th,30th,45th and 60th day. <br/ ><br>